Neutrophil/lymphocyte and platelet/lymphocyte ratio and outcome after first chemotherapy of patients with breast cancer in a city of Minas Gerais
DOI:
https://doi.org/10.30968/rbfhss.2024.152.1127Abstract
Aim. To evaluate the factors associated with the pre and post-first chemotherapy inflammatory response in cancer patients, by determining the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) in the breast cancer population in Barbacena, and to verify their contribution to the observed outcome. Methods. Retrospective study, including 152 breast cancer patients in a reference hospital in Barbacena, MG, between 2016 and 2021. The results of complete peripheral blood counts before any therapeutic procedure (baseline blood count - surgery, radiotherapy, or chemotherapy) were collected, as well as follow-up exams. Additionally, data regarding the outcome of the first treatment and/or date of disease progression or death were also collected. The NLR was obtained by the ratio of the absolute neutrophil count to the absolute lymphocyte count. The PLR was calculated by dividing the absolute number of platelets by the absolute number of lymphocytes. The median NLR and PLR were calculated, and the data were processed using JASP statistical software v. 16.4.0. Results. It was observed that both alterations in NLR and PLR were predictors of outcome, with patients showing higher NLR (p = 0.034) and PLR (p = 0.043) in the post-first cycle of treatment blood count for disease progression or death. The effect size for both relationships was 0.218. Conclusion. NLR and PLR are useful as predictors of post-first treatment outcome in breast cancer patients.
Downloads
References
Bray F, Laversanne M, Sung H, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians 2024; 74(3): 229-263. DOI: 10.3322/caac.21834.
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2023.
Pedersen RN, Esen BÖ, Mellemkjær L, et al. The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. J Natl Cancer Inst. 2022; 114(3):391-399. DOI: 10.1093/jnci/djab202.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899. DOI: 10.1016/j.cell.2010.01.025.
Graziano V, Grassadonia A, Iezzi L, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019; 44:33-38. DOI: 10.1016/j.breast.2018.12.014.
Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. DOI: 10.1093/jnci/dju124.
Abbas, AK; Lichtman, AH; Pillai, S. Imunologia Celular e Molecular. 8ᵃEdição. Elsevier, 2015.
Zhang W, Shen Y, Huang H, et al. A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment. Front Immunol. 2020;11:1779. DOI: 10.3389/fimmu.2020.01779.
Li M, Spakowicz D, Burkart J, et al. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J Cancer Res Clin Oncol. 2019;145(10):2541-2546. DOI: 10.1007/s00432-019-02982-4.
Ethier JL, Desautels D, Templeton A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2. DOI: 10.1186/s13058-016-0794-1.
Balta S, Ozturk C. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets. 2015;26(7):680-1. DOI: 10.3109/09537104.2014.979340.
Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol. 2018;25(7):1783-1785. DOI: 10.1245/s10434-018-6486-6.
Cuello-López J, Fidalgo-Zapata A, López-Agudelo L, et al. Platelet-to-lymphocyte ratio ss a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. PLos Um. 2018; 13(11):e0207224. DOI: 10.1371/journal.pone.0207224.
Asano Y, Kashiwagi S, Onoda N, et al. Platelet-Lymphocyte Ratio as a useful predictor of the therapeutic effect of neoadjuvant chemotherapy in breast Cancer. PLos Um. 2016;11(7):e0153459. DOI: 10.1371/journal.pone.0153459.
Al Jarroudi O, El Bairi K, Abda N, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer. Biomark Med. 2021;15(14):1289-1298. DOI: 10.2217/bmm-2020-0717. Epub 2021 Sep 6.
Silva SHK da, Oliveira LC de, Peres WAF, et al. A relação neutrófilo-linfócito pré-tratamento tem valor prognóstico em pacientes com câncer de mama. RSD [Internet]; 11(9):e17611931783. Available in: https://rsdjournal.org/index.php/rsd/article/view/31783. Accessed on 22 November 2022.
von Au A, Shencoru S, Uhlmann L, et al. Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer. Arch Gynecol Obstet. 2023; 307(4): 1105–1113; . DOI: 10.1007/s00404-022-06726-7.
Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360. DOI: 10.1186/s12916-020-01817-1.
Kim JH, Son NH, Lee JS, et al. Sequenciamento temporal da Relação Neutrófilo-Linfócito para Prever Prognóstico do Câncer de Mama Triplo-Negativo. Cânceres (Basileia). 2021;13(14):3472. DOI: 10.3390/cancers13143472.
Kim JY, Jung EJ, Kim JM, et al. Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis. BMC Cancer. 2020;20(1):1206. DOI: 10.1186/s12885-020-07700-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
